Page last updated: 2024-11-02

pamidronate and Carcinoma

pamidronate has been researched along with Carcinoma in 11 studies

Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.

Research Excerpts

ExcerptRelevanceReference
"Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial."9.11Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004)
"To identify markers sensitive to inhibitors of the farnesylation pathway, we used 3 breast cancer cell lines (SKBR-3, MDA-175, and MDA-231) to evaluate the in vitro effects of pamidronate, an inhibitor of farnesyl diphosphate synthase."7.72Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. ( Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL, 2004)
"Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains."5.30Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. ( Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998)
"Parathyroid carcinoma is rare and the associated hypercalcaemia is often resistant to all treatment."5.29Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. ( Braatvedt, GD; Corrall, RJ; Newrick, PG; Sheffield, E; Webb, AJ, 1994)
"Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial."5.11Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004)
" Pamidronate, an inhibitor of bone resorption used primarily in the management of tumor-induced hypercalcemia and Paget's disease, is reported to cause conjunctivitis, anterior uveitis, and infrequently episcleritis and scleritis."3.72Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports. ( Claes, C; Haverbeke, G; Pertile, G; Zeyen, T, 2003)
"To identify markers sensitive to inhibitors of the farnesylation pathway, we used 3 breast cancer cell lines (SKBR-3, MDA-175, and MDA-231) to evaluate the in vitro effects of pamidronate, an inhibitor of farnesyl diphosphate synthase."3.72Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. ( Blasick, TM; Brown, RE; Lun, M; Siegelmann-Danieli, N; Zhang, PL, 2004)
"We present a case of undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy (HHM) in which parathyroid hormone-related protein (PTH-rP) is identified as the causative factor of hypercalcemia."2.40Undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy. ( Higuchi, T; Kakizaki, S; Kitazawa, R; Mori, M; Nagamine, T; Ohya, N; Takagi, H; Takayama, H; Yoshinaga, T, 1998)
"Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains."1.30Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. ( Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998)
"Parathyroid carcinoma is rare and the associated hypercalcaemia is often resistant to all treatment."1.29Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate. ( Braatvedt, GD; Corrall, RJ; Newrick, PG; Sheffield, E; Webb, AJ, 1994)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (45.45)18.2507
2000's5 (45.45)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pittaway, JF1
Srirangalingam, U1
Hanson, PL1
Jones, P1
Drake, WM1
Rosen, LS1
Gordon, DH1
Dugan, W1
Major, P1
Eisenberg, PD1
Provencher, L1
Kaminski, M1
Simeone, J1
Seaman, J1
Chen, BL1
Coleman, RE1
Haverbeke, G1
Pertile, G1
Claes, C1
Zeyen, T1
Zhang, PL1
Lun, M1
Siegelmann-Danieli, N1
Blasick, TM1
Brown, RE1
Hay, KD1
Bishop, PA1
Engroff, SL1
Kim, DD1
Newrick, PG1
Braatvedt, GD1
Webb, AJ1
Sheffield, E1
Corrall, RJ1
Vainas, IG1
Tsilikas, C1
Grecu, A1
Pasaitu, K1
Stergiou, I1
Kortsaris, AH1
Cascinu, S1
Graziano, F1
Alessandroni, P1
Ligi, M1
Del Ferro, E1
Rossi, D1
Ficarelli, R1
Catalano, G1
Cömlekçi, A1
Biberoglu, S1
Hekimsoy, Z1
Okan, I1
Pişkin, O1
Sekeroglu, B1
Alakavuklar, M1
Kakizaki, S1
Ohya, N1
Yoshinaga, T1
Higuchi, T1
Kitazawa, R1
Takayama, H1
Takagi, H1
Nagamine, T1
Mori, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420]Phase 14 participants (Actual)Interventional2005-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for pamidronate and Carcinoma

ArticleYear
Metastatic parathyroid carcinoma (mPCa): natural history and treatment of a case.
    Journal of experimental & clinical cancer research : CR, 1997, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Calcitonin; Carcinoma; Diagnosis, Differential; Diphosphonates; Humans; Lung

1997
Undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy.
    Japanese journal of clinical oncology, 1998, Volume: 28, Issue:9

    Topics: Antineoplastic Agents; Carcinoma; Diphosphonates; Humans; Hypercalcemia; Liver Neoplasms; Male; Midd

1998

Trials

2 trials available for pamidronate and Carcinoma

ArticleYear
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
    Cancer, 2004, Jan-01, Volume: 100, Issue:1

    Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Re

2004
Different doses of pamidronate in patients with painful osteolytic bone metastases.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1998, Volume: 6, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Diphosphonates; Female; Humans; Male;

1998

Other Studies

7 other studies available for pamidronate and Carcinoma

ArticleYear
Renal replacement therapy as a treatment for severe refractory hypercalcemia.
    Minerva endocrinologica, 2014, Volume: 39, Issue:3

    Topics: Adenoma; Adult; Carcinoma; Cinacalcet; Diphosphonates; Drug Resistance; Emergencies; Female; Furosem

2014
Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports.
    Bulletin de la Societe belge d'ophtalmologie, 2003, Issue:290

    Topics: Bone Neoplasms; Bone Resorption; Carcinoma; Conjunctivitis; Diphosphonates; Fatal Outcome; Humans; M

2003
Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy.
    Annals of clinical and laboratory science, 2004,Summer, Volume: 34, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Br

2004
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
    The New Zealand dental journal, 2006, Volume: 102, Issue:1

    Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, T

2006
Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction?
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2007, Volume: 65, Issue:11

    Topics: Bone Density Conservation Agents; Bone Plates; Bone Transplantation; Breast Neoplasms; Carcinoma; Di

2007
Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate.
    Postgraduate medical journal, 1994, Volume: 70, Issue:821

    Topics: Calcium; Carcinoma; Diphosphonates; Female; Humans; Hypercalcemia; Middle Aged; Pamidronate; Parathy

1994
Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
    Internal medicine (Tokyo, Japan), 1998, Volume: 37, Issue:4

    Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Carcinoma; Diphosphonates;

1998